Is Pediatric Exclusivity Working?
- 16 October 2007
- journal article
- Published by Taylor & Francis in Pediatric Health
- Vol. 1 (1) , 43-49
- https://doi.org/10.2217/17455111.1.1.43
Abstract
No abstract availableKeywords
Funding Information
- National Center for Research Resources and NIH (1UL 1RR024128–01)
This publication has 10 references indexed in Scilit:
- Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity ProgramJAMA, 2007
- Stimulation programs for pediatric drug research – do children really benefit?European Journal of Pediatrics, 2007
- Peer-Reviewed Publication of Clinical Trials Completed for Pediatric ExclusivityJAMA, 2006
- Atovaquone-Proguanil versus Chloroquine-Proguanil for Malaria Prophylaxis in Nonimmune Pediatric Travelers: Results of an International, Randomized, Open-Label StudyClinical Infectious Diseases, 2004
- Pediatric Drug LabelingJAMA, 2003
- Efficacy of Atovaquone/Proguanil for Malaria Prophylaxis in Children and Its Effect on the Immunogenicity of Live Oral Typhoid and Cholera VaccinesClinical Infectious Diseases, 2002
- An Update on the Therapeutic OrphanPediatrics, 1999
- Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in childrenThe Pediatric Infectious Disease Journal, 1999
- Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in childrenThe Lancet, 1998
- Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria.Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998